Today in an exciting collaborative effort, three major Parkinson’s disease (PD) advocacy organizations have joined forces to issue a...see more public statement imploring lawmakers to robustly fund the National Institutes of Health (NIH) in the upcoming federal budget in order to keep Parkinson’s disease (PD) research moving forward as quickly as possible. This important joint statement […]

Read More

A recent study in Journal of the American Medical Association...see more has caused a stir, showing that living near golf courses is associated with an increased risk of Parkinson’s disease (PD). The study demonstrated that those living within a mile of a golf course had a 2.25 times increased […]

Read More

In exciting news, the FDA approved Medtronic’s deep brain stimulation (DBS) system known...see more as BrainSense™. Unlike standard DBS, which delivers electricity to the brain at pre-programmed settings, this technology can sense the brain’s electric signals, known as local field potentials or LFPs, and adjust the stimulation accordingly. This capability, […]

Read More

ONAPGOTM: A Newly-Approved Medication for OFF Periods in Parkinson’s Breaking News! The first subcutaneous (under the skin) apomorphine infusion,...see more now called ONAPGOTM, was approved by the Food and Drug Administration (FDA) on February 4, 2025. Apomorphine is a dopamine agonist whose effects have a rapid onset. It has been available in the US as a […]

Read More

In an exciting development for the Parkinson’s disease (PD) community, the Environmental Protection Agency (EPA) banned two solvents, trichloroethylene...see more (TCE) and perchloroethylene, that are found in many common industry and household products such as cleaners, lubricants, and glue. Both have been found to contribute to the increased risk of various cancers and other health conditions. […]

Read More

Breaking news! The first subcutaneous (under the skin) 24-hour infusion...see more of foslevodopa/foscarbidopa under the brand name Vyalev, was approved by the Food and Drug Administration on Oct 17, 2024. Produced by AbbVie, this medication for the treatment of motor fluctuations in Parkinson’s disease (PD) has already […]

Read More

Deep brain stimulation (DBS) is a surgical procedure in which thin electrodes are implanted into parts of the brain...see more to alter brain circuitry. It is used in the treatment of several neurologic conditions including Parkinson’s disease (PD), in which the electricity disrupts abnormal brain signals that allows the brain to restore more normal movement. Currently, […]

Read More

APDA-funded researchers at Brigham and Women’s Hospital, including Drs. Isabel Lam and Anastasia Kuzkina, under the leadership of Dr. ...see more Vikram Khurana, the Director of APDA’s Center for Advanced Research at Brigham and Women’s Hospital, recently published a paper demonstrating a novel technology that more rapidly turns stem cells created from the cells of an adult […]

Read More

New Carbidopa/Levodopa Formulation Approved for Reducing OFF Time Amneal Pharmaceuticals, Inc. announced today that their new medication IPX203, now known as...see more Crexont®, was approved by the Food and Drug Administration. Crexont is a novel oral formulation of carbidopa-levodopa extended-release capsules. Similar to Amneal’s Rytary, it contains both immediate-release and extended-release elements in the capsule and is designed […]

Read More

Today, Congresswoman Jennifer Wexton announced the introduction of a new bill which aims to fund research into environmental causes...see more of neurodegenerative disease. Wexton, a Democrat from Virginia, has been diagnosed with Progressive Supranuclear Palsy, a form of atypical parkinsonism, which has significantly impacted her movement, gait, and speech. As a member of Congress, she has […]

Read More